Safety, feasibility and preliminary efficacy of single agent combretastatin A1 diphosphate (OXi4503) in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndromes. - Cogle CR; Collins B; Turner D; Pettiford LC; Bossé R; Hawkins KE; Beachamp Z; Wise E; Cline C; May WS; Moreb JS; Hsu J; et al. (British journal of haematology, 2020)